Tevogen expands T cell therapy pipeline across viral and cancer indications
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
January 12, 2026 9:00 AM ESTJan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference
WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (Tevogen Bio Holdings Inc. or Company) (Nasdaq: TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogens continued execution toward a scalable, established, multi-program cell... More
